Earlier this week, a small San Diego company named Organovo (NYSEMKT:ONVO) filed its annual report with the SEC. Since then, shares have traded down by as much as 18%.
This appears to be in response to a posting on Seeking Alpha which opined that "Management's obfuscation in its reporting underscores its controversial nature. It undermines management's credibility and lends credence to bears' view that its long-term value proposition of printing human organs is a myth."
While Organovo is often referred to as a company with such a goal, this goal has been thoroughly discussed and is actually a very small part of what the company hopes to accomplish in the near future.
In the slide show below, we'll examine the two big take-aways from the company's report, and whether or not it warrants such a price correction.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Brian Stoffel owns shares of Organovo, though they make up less than 0.1% of his overall holdings. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.